Clinical Trial Update: SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab [Phase 1]

View source ↗

Summary

Phase 1 update of SX-682 in metastatic melanoma patients treated with pembrolizumab (stages III/IV); the trial is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• SX-682

Snippet

Sponsor: Syntrix Biosystems, Inc. | Conditions: Melanoma Stage III, Melanoma Stage IV | Phase 1 | Status: ACTIVE_NOT_RECRUITING